Picoplatin is a platinum-based antineoplastic agent used for the treatment of solid tumors. It was developed to overcome resistance to other platinum drugs and exhibits reduced neurotoxicity and nephrotoxicity. Picoplatin has demonstrated antitumor activity in various cancers, including lung cancer, ovarian cancer, colorectal cancer, and hormone-refractory prostate cancer. Clinical trials have advanced to Phase III for lung cancer, Phase II for colorectal and prostate cancers, and Phase I for oral administration. It functions by inhibiting DNA replication and transcription and inducing apoptosis in tumor cells. Despite failing to meet the primary endpoint in a Phase III trial for advanced small cell lung cancer (SCLC), it remains under investigation, particularly for metastatic colorectal cancer.